- The Data Gold Rush: Opportunities for pharma on secondary uses of healthcare data – Steve Labkoff, Deloitte
- HIPAA Challenges Ahead in Mining Patient-Centric Data– Kristen Rosati, Coppersmith Scheermer & Brockelman
- Exploring the Clinical Informatics Landscape in Europe, Asia and Beyond – Ken Park, McKinsey
- Five Year Trends in Spending by Disease: Results from the MarketScan Database – Bill Mardar, Thompson Reuters
- Advanced Analytic Methods for Evidenc-based Clinical Research: Using clinical data and analytic methods to improve our understanding of disease-state and therapeutic effect – John Murphy, Quintiles
- Data in the Healthcare Ecosystem: The relationship between pharma and the ACO – Douglas Cusick, HP
- Secondary Use of Electronic Health Record (ER) Data: Creating value for healthcare provider and life sciences organisations – Paul Bleicher, Humedica
- EMR Data Mining for Drug Safety: Challenges and Opportunities – John Cai, AZ
- Informatics Opportunities for Exploring the Real-World Effects of Medical Products: Lessons from the Observational Medical Outcomes Partnership– Patrick Ryan, OMOP Research Team
- Defining Phenotypes: Genetic Studies – Marsha Wilcox, J&J
- PRISM Forum SIG: Summary– Jim McGurk, Daiichi Sankyo
